Visão geral da empresa
A biopharmaceutical enterprise dedicated to the development and commercialization of novel therapeutics, Madrigal Pharmaceuticals, Inc. concentrates its operational efforts on addressing metabolic dysfunction-associated steatohepatitis, commonly referred to as MASH, within the United States market. The company currently offers Rezdiffra, which functions as a liver-directed thyroid hormone receptor beta agonist specifically engineered for the treatment of MASH conditions. Operating within the Healthcare sector and the Biotechnology industry, the firm targets a specialized therapeutic area where precision medicine and biological interventions are critical for patient outcomes. In terms of scale, the company commands a substantial market capitalization of $11.92 billion and generates annual revenue of $958.40 million, supported by a workforce of 915 employees. These valuation figures indicate that Madrigal is a large-cap entity with significant market presence, reflecting high investor confidence in its proprietary asset pipeline and the substantial commercial potential of its core product offering in the evolving landscape of liver disease treatments.
Saúde financeira
The company reported revenue of $958.40 million over the trailing twelve-month period, yet recorded a net income of -$288.284 million and an EBITDA of -$298.591 million, revealing a substantial gap between top-line sales and bottom-line profitability driven by significant operating expenses. This disparity highlights a cost structure typical of early-stage commercialization or heavy R&D investment phases, where revenue generation does not yet offset the extensive costs required to sustain clinical trials and manufacturing scale-up. Free cash flow stood at -$115.079752 million, indicating that the company is currently burning cash to fund its operations and growth initiatives rather than generating liquidity from daily business activities. Despite this negative cash flow, the balance sheet maintains robust liquidity with $983.56 million in cash against total debt of $347.63 million, suggesting a conservative financial posture with ample resources to cover obligations. The debt-to-equity ratio is recorded at 57.68, which, when viewed alongside the high cash reserves, suggests a manageable leverage level for a biotechnology firm with significant intangible assets. Liquidity is further secured by a current ratio of 4.01, a figure that indicates a very strong ability to meet short-term liabilities with its current assets, providing a wide safety margin against immediate financial pressures. Return on equity is -42.5% and return on assets is -16.3%, metrics that reveal the company is currently diluting shareholder value and utilizing assets to generate losses rather than profits, a common characteristic for biotech firms awaiting pivotal data readouts or product approvals.
Avaliação de valorização
Valuation metrics present a complex picture where the P/E ratio (TTM) is listed as N/A due to the negative net income, while the forward P/E is calculated at 40.62, implying that the market prices the stock based on expected future earnings that are anticipated to turn positive. The price-to-book ratio stands at 19.70, indicating a significant market premium over the company's book value, which suggests investors are valuing the firm's intellectual property and pipeline at a multiple far exceeding its tangible asset base. Alternative valuation measures include a price-to-sales ratio of 12.44 and an EV/EBITDA of -37.80, suggesting that investors are willing to pay a high multiple for revenue given the potential for the MASH franchise, despite the current negative earnings multiple. The stock has traded within a range defined by a 52-week high of $615.00 and a 52-week low of $265.00, placing the current trading price well below the recent peak but maintaining a position that reflects the volatility inherent in biotechnology equities. The beta value of -1.01 is an anomalous metric that indicates price movements inversely correlated to the broader market, suggesting the stock reacts differently than typical market assets during periods of economic fluctuation.
Growth & Income
Revenue growth year-over-year has accelerated dramatically to 210.8%, driven likely by the commercial launch and adoption of Rezdiffra, while earnings growth is listed as N/A due to the company's current unprofitability. The divergence between the explosive revenue expansion and the absence of earnings growth implies that the company is prioritizing market share capture and revenue scale over immediate profitability, a strategy common in the biotechnology sector. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that it retains all net income and cash flows to reinvest into research and development, clinical trials, and market expansion rather than distributing returns to shareholders. The overall growth and income profile is characterized by rapid top-line expansion funded by existing cash reserves, with no current income generation from dividends but high potential for future earnings once the company achieves sustained profitability.